Cogent Biosciences (COGT) Change in Account Payables (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of Change in Account Payables data on file, last reported at $4.2 million in Q1 2026.

• On a quarterly basis, Change in Account Payables rose 98.04% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was -$410000.0, a 70.94% increase from a year earlier, with the FY2025 full-year figure at -$2.5 million, down 284.76% from the prior year.
• Change in Account Payables for Q1 2026 stood at $4.2 million, up from -$6.5 million in the prior quarter.
• Over the last five years, Change in Account Payables for COGT reached as high as $6.1 million in Q3 2024 and fell as low as -$6.6 million in Q2 2024.
• Historically, Change in Account Payables has averaged $603588.2 across 5 years, with a median of $787000.0 in 2023.
• Across the five-year window, Change in Account Payables surged 671.51% in 2023 and slumped 487.29% in 2024, its largest moves.
• Year by year, Change in Account Payables stood at $1.7 million in 2022, then plunged by 55.0% to $787000.0 in 2023, then slumped by 487.29% to -$3.0 million in 2024, then slumped by 114.07% to -$6.5 million in 2025, then soared by 164.98% to $4.2 million in 2026.
• Per Business Quant data, the three most recent Change in Account Payables figures were $4.2 million in Q1 2026, -$6.5 million in Q4 2025, and -$596000.0 in Q3 2025.